Another targeted therapy group is that with CDKi, mainly represented in our study by palbociclib, which has been approved for hormone receptor positive, HER2/neu-negative, locally advanced or metastasized breast cancer in combination with an aromatase inhibitor [20]. Here, CYP19A1 is linked to breast cancer.